


CLINICAL



Overview of the phase 3 clinical development program for investigational biweekly (once every two weeks) GLP-1 RA Bofanglutide (GZR18) injection

The clinical development program currently focuses on three indications: obesity/overweight, type 2 diabetes and moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, evaluating the efficacy and safety of biweekly GLP-1 RA bofanglutide (GZR18) injection, with a planned total enrollment of more than 2,700 adults

GRADUAL Obesity Program and OPTIMUM Type 2 Diabetes Program

- GRADUAL-1**

Adults with obesity or overweight
- GRADUAL-2**

Obese or overweight adults with or without T2D
- GRADUAL-3**

Adults with obesity or overweight
- GRADUAL-OSA-1**

Adults with OSA and obesity not treated with PAP therapy
- GRADUAL-OSA-2**

Adults with OSA and obesity treated with PAP therapy
- OPTIMUM-1**

Adults with T2D inadequately controlled with diet and exercise alone
- OPTIMUM-2**

Adults with T2D inadequately controlled on OADs



Note: Study start dates are based on Gan & Lee's official press releases, while projected completion dates are based on estimated timelines registered on ClinicalTrials.gov.



- Global development program**
- Phase 3 program in China:**

 - Aim to confirm efficacy and safety across seven large-scale phase 3 trials
- Phase 2 global program:**

 - Phase 2 study comparing bofanglutide with placebo in participants with obesity or overweight


GRADUAL-1

Biweekly GLP-1 RA bofanglutide injection vs. placebo in Chinese adults with obesity or overweight




GRADUAL-2

Biweekly GLP-1 RA bofanglutide injection vs. semaglutide (Wegovy®) in Chinese adults with obesity or overweight




Inclusion criteria:

- Female or male, age ≥ 18
- Obese ($\text{BMI} \geq 28 \text{ kg/m}^2$) or overweight ($24 \text{ kg/m}^2 \leq \text{BMI} < 28 \text{ kg/m}^2$) with at least one comorbidity, including up to 20% of participants with T2D



GRADUAL-3

Biweekly GLP-1 RA bofanglutide injection vs. placebo in the extension study for weight loss







Inclusion criteria:

- Female or male, age ≥ 18
- Completed the original study, with a last dose ≥ 24 mg
- BMI ≥ 18.5 kg/m²






GRADUAL-OA-1

Biweekly GLP-1 RA bofanglutide injection vs. placebo in obese participants with moderate to severe OSA not treated with PAP therapy





GRADUAL-OA-2

Biweekly GLP-1 RA bofanglutide injection vs. placebo in obese participants with moderate to severe OSA receiving PAP Therapy





OPTIMUM-1

Biweekly GLP-1 RA bofanglutide injection vs. placebo in Chinese adults with type 2 diabetes inadequately controlled with diet and exercise alone



OPTIMUM-2

Biweekly GLP-1 RA bofanglutide injection vs. semaglutide (Ozempic®) in Chinese adults with type 2 diabetes inadequately controlled by metformin monotherapy or metformin in combination with SGLT2 inhibitor or sulfonylurea



Abbreviations

Biweekly, once every two weeks, Q2W; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c , glycated hemoglobin; s.c., subcutaneous; T2D, type 2 diabetes; OSA, Obstructive Sleep Apnea; PAP, Positive Airway Pressure; OADs, Oral Antidiabetic Drugs; AHI, Apnea-Hypopnea Index; H2H, Head-to-Head; BMI, Body Mass Index; TEAEs, treatment-emergent adverse events; SGLT2, sodium-dependent glucose transporter 2;

Glossary

Comorbidity of one or more of the following:

- hyperglycemia, hypertension, dyslipidemia, or fatty liver;
- Weight-bearing joint pain;
- Weight-related obstructive sleep apnea syndrome.

References

GRADUAL-1: NCT06728124. ClinicalTrials.gov. <https://clinicaltrials.gov/study/NCT06728124>

GRADUAL-2: NCT07150975. ClinicalTrials.gov. <https://clinicaltrials.gov/study/NCT07150975>

GRADUAL-3: NCT07292441. ClinicalTrials.gov. <https://clinicaltrials.gov/study/NCT07292441>

GRADUAL-OSA-1: NCT07493057. ClinicalTrials.gov. <https://clinicaltrials.gov/study/NCT07493057>

GRADUAL-OSA-2: NCT07501832. ClinicalTrials.gov. <https://clinicaltrials.gov/study/NCT07501832>

OPTIMUM-1: NCT06777238. ClinicalTrials.gov. <https://clinicaltrials.gov/study/NCT06777238>

OPTIMUM-2: NCT06778967. ClinicalTrials.gov. <https://clinicaltrials.gov/study/NCT06778967>